The North America Diabetic Retinopathy Market would witness market growth of 10.8% CAGR during the forecast period (2021-2027).
The market is also being driven by an increase in the prevalence of diabetes, a rise in the geriatric population, an increase in the incidence of diabetes-related blindness, and a greater focus on earlier detection to control diseases. In contrast, the advent of combination therapies for the therapeutics of diabetic macular edema, as well as expanding markets in various countries all over the world, are likely to create numerous prospects for the growth of the diabetic retinopathy market over the coming years.
The treatment of diabetic retinopathy is determined by the symptoms, age, and overall health statistics of the patient. It can also be defined by the severity of the ailment. If advanced retinopathy is treated before the retina is significantly damaged, people in advanced stages of retinopathy have a fair chance of retaining their eyesight. The vitreous that occupies the center of the eye is removed during vitrectomy surgery.
According to the Centers for Disease Control and Prevention (CDC), around 100 million Americans have diabetes, which is one of the leading causes of blindness. The regional market is also growing as people become more aware of sophisticated solutions for treating diabetic retinopathy. The diabetic retinopathy market in North America is highly competitive. For example, Bayer AG is a leading pharmaceutical company in the United States that has dominated the market by producing high-quality diabetic retinopathy treatments. As a result, new entrants should weigh the risks of entering into a competitive market. The regional market is also growing because of the favorable reimbursement policies and the rising diabetes prevalence. One of the key factors leading to the huge regional share is the high market penetration of anti-VEGF medications such as Avastin, Elea, and Lucentis.
The US market dominated the North America Diabetic Retinopathy Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $2,103.7 Million by 2027. The Canada market anticipated to grow at a CAGR of 13.3% during (2021 - 2027). Additionally, The Mexico market would display a CAGR of 12.3% during (2021 - 2027).
Based on Type, the market is segmented into Proliferative and Diabetic Macular Edema (DME). Based on Treatment Type, the market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Diabetic Retinopathy Market is Estimated to reach $7.7 Billion by 2027, at a CAGR of 11.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.
By Type
By Treatment Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
